Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.
first published: May 8, 2013 11:14 am
A collection of the most-viewed Moneycontrol videos.
Live: Can Nifty reclaim record levels as investors await FOMC decision this week? | Opening Bell
Why This Tenant Says Bandra Is Better Than California | The Tenant
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
